Acinetobacter baumannii and multiple antibiotic resistances
Abstract
Acinetobacter baumannii is a strict aerobic gran negative coccobacillus, able to acquire multiple resistance to broad-spectrum antibiotics due to its ability to take fragments of genetic material from other bacteria, for further incorporation of this material into its own chromosome. Acinetobacter baumannii is the cause of several nosocomial infections and of numerous outbreaks in hospitals over different continents. This paper includes a literature review of scientific articles published since January 2010 about this microorganism, its environment, mechanisms of resistance and virulence, as well as commonly used treatment.Downloads
References
World Health Organization (WHO). The evolving threat of antimicrobial resistance Options for action. http://whqlibdoc.who.int/publications/2012/9789241503181_eng.pdf. (Consultado el 23 de febrero de 2013)
Lye, D. C., Earnest, A, Ling, M. L., Lee, T.-E., Yong, H.-C., Fisher, D. a. et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012. 18(5), 502–8.
Pendleton JN , Gorman SP , Gilmore BF . Clinical relevance of the ESKAPE pathogens. Expert Rev. anti Infect Ther. 2013; 11 (3) :297-308.
Leal A, Buitrago G, Sanchez R, Castillo Juan, Cortes Jorge, Álvarez C, et al. The emergence of multidrug-resistant Acinetobacter baumannii in Colombia: A time-series analysis, 2001-2007. Rev. Salud pública.2011. 13 (4): 691-702.
Brigante T , Migliavacca R , S Bramati , Motta E , Nucleo E , Manenti M. Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. J Med Microbiol. 2012 May; 61 (Pt 5) :653-61
Zuñiga A., Chavez M., Gómez R., Cabrera C., Corral R., López B. Relación entre virulencia y resistencia antimicrobiana en Acinetobacter baumannii. NOVA 2010.8(14), 148–162.
Visca, P., Seifert, H., & Towner, K. J. Acinetobacter infection--an emerging threat to human health. IUBMB life. 2011; 63(12), 1048–54.
Cortes, J. A., Leal, A. L., Montañez, A. M., Buitrago, G., Castillo, J. S., & Guzman, L. Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2013; 17(3).346–52.
Hernández A, García E, Yagüe G, Gómez J. Acinetobacter baumannii multirresistente: situación clínica actual y nuevas perspectivas. Rev.Esp.Quimioter 2010;23(1):12-19
Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii an emerging opportunistic pathogen. Virulence. 2012 May 1; 3(3):243-50.
Galvis C, Villabón G, Ortiz Karla. Factores asociados a infección por Acinetobacter Baumannii en una unidad de cuidados intensivos en Bogotá D.C. http://repository.urosario.edu.co/bitstream/10336/2671/1/53010064-2011.pdf (consultado el 23 de febrero de 2013).
Espinal, P., Martí, S., & Vila, J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. The Journal of hospital infection. . 2012; 80(1). 56–60.
Lourdes, M. De, Ramirez, P., Coapa, V., & Madrazo, M. Artículo original Acinetobacter Baumanni y resistencia a los antimicrobianos en un hospital de segundo nivel de la ciudad de México. Revista de Enfermedades Infecciosas en Pediatría. 2013 Vol XXVI Núm 104.300-306.
Prata M, Gontijo P, Melo G. Factors influencing survival in patients with multidrug-resistant Acinetobacter baumannii infection. Braz J Infect.Dis. 2012 Jun; 16(3):237-41.
Dent L, Marshall D, Pratap S,Hulette R. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infectious Diseases 2010, 10:196
Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC, SENTRY Participants Group (Latin America). SENTRY Antimicrobial Surveillance Program Report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis. 2004;8:25–79.)
Reguero, M. T., Medina, O. E., Hernández, M. A., Flórez, D. V., Valenzuela, E. M., & Mantilla, J. R. Antibiotic resistance patterns of Acinetobacter calcoaceticus-A. baumannii complex species from Colombian hospitals. Enferm Infecc Microbiol Clin. 2013;31(3):142–146
Lemos EV, De la Hoz Restrepo F, Alvis N, Quevedo E, Cañon O, León Y. Mortalidad por Acinetobacter baumannii en unidades de cuidados intensivos en Colombia. Rev Panam Salud Pública. 2011; 30(4): 287–94.
Chen Y, Lu P, Huang Ch, Liao Ch, Lu Ch, Chuang Y, et al. Trends in the Susceptibility of Clinically Important Resistant Bacteriato Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010. Antimicrob Agentes Chemother; 2012 Marzo; 56 (3): 1452-57.
Shin J, Chang Y, Kim H, Kim S, Chang J, AhnCh, et al. Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection. Yonsei Med J. 2012 September 1; 53(5): 974–984
Piparsania, S., Rajput, N., & Bhatambare, G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi- resistant Acinetobacter baumannii – case report and review of literatura. The Turkish Journal of Pediatrics 2012; 54: 548-554
.png)
